ArticleEuropean journal of nuclear medicine and molecular imaging2015

Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab.

Kristoff Muylle et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.